The results of two independent, observational studies suggest that antidiabetic medications might have differential effects on cancer risk in patients with diabetes mellitus. Should these findings influence our approach to diabetes treatment?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Scientific Reports Open Access 17 March 2016
-
TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations
Nature Communications Open Access 13 August 2015
-
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies
Scientific Reports Open Access 15 June 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hemkens, L. G. et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732–1744 (2009).
Libby, G. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620–1625 (2009).
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G. & Vigneri, R. Diabetes and cancer. Endocr. Relat. Cancer doi:10.1677/ERC-09-0087.
Kurtzhals, P. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49, 999–1005 (2000).
Hansen, B. F. Insulin analogues with increased mitogenic potency – are they safe? Horm. Metab. Res. 40, 431–433 (2008).
Jonasson, J. M. et al. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52, 1745–1754 (2009).
Colhoun, H. M. et al. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52, 1755–1765 (2009).
Currie, C. J., Poole, C. D. & Gale, E. A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766–1777 (2009).
Vigneri, P., Frasca, F., Sciacca, L., Frittitta, L. & Vigneri, R. Obesity and cancer. Nutr. Metab. Cardiovasc. Dis. 16, 1–7 (2006).
Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorhythm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares an association with the following company: Sanofi-Aventis (speaker; grant/research support)
Rights and permissions
About this article
Cite this article
Vigneri, R. Diabetes therapy and cancer risk. Nat Rev Endocrinol 5, 651–652 (2009). https://doi.org/10.1038/nrendo.2009.219
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.219
This article is cited by
-
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Scientific Reports (2016)
-
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies
Scientific Reports (2015)
-
TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations
Nature Communications (2015)
-
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients
Acta Diabetologica (2014)
-
Higher level of serum vascular endothelial growth factor in type 2 diabetic patients with diabetic retinopathy hospitalized for hyperglycemic state
Diabetology International (2011)
